Bio-Thera Solutions has found a partner to help with US distribution of its proposed ustekinumab biosimilar, which entered phase 3 trial development this summer.
Guangzhou, China-based Bio-Thera Solutions has partnered with UK-based Hikma Pharmaceuticals for the commercialization of a proposed ustekinumab biosimilar (BAT2206) for the treatment of chronic inflammation.
BAT2206 references Stelara, which was developed by Janssen Biotech. In the United States, Stelara is approved for the treatment of psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Hikma would have rights for US commercialization of BAT2206 and first rights to negotiate marketing in the European Union. “This partnership provides us with a unique opportunity to enter the biosimilar market in the United States,” said Siggi Olafsson, CEO of Hikma.
In July 2021, Bio-Thera announced the first dosing of a patient in a phase 3 clinical study for BAT2206. The randomized, double-blind, parallel controlled study will compare the efficacy and safety of BAT2206 with Stelara in patients with moderate-to-severe psoriasis. Projected enrollment is 472 individuals in the United States and European Union.
Ustekinumab is a monoclonal antibody that suppresses the action of cytokines (interleukin 12/23) that contribute to the body’s inflammatory response.
Bio-Thera is developing biosimilars for bevacizumab (Avastin) and tocilizumab (Actemra), for the treatment of certain cancers and rheumatoid arthritis (RA), respectively. These pipeline products have completed phase 3 trials. The company is also developing golimumab (Simponi; RA), mepolizumab (Nucala; asthma), and dupilumab (Dupixent; asthma, eczema) biosimilars.
Hikma was founded in Jordan in 1978 and now has various FDA-inspected manufacturing sites globally. The company recently acquired Roxane Laboratories in Columbus, Ohio, in a move to build its non-injectables business.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.